OGEN vs SIGA vs NVAX vs DYAI vs OCGN vs JPM

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -64. 7% for Dyadic International, Inc. (DYAI). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate SIGA Technologies, Inc. (SIGA) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus JPMorgan Chase & Co. at 16. 2x. On forward P/E, SIGA Technologies, Inc. is actually cheaper at 2. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -100. 0% for Oragenics, Inc. (OGEN). Over 10 years, the gap is even starker: SIGA returned +642. 9% versus OGEN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 87β versus Novavax, Inc. 's 2. 05β — meaning NVAX is approximately 136% more volatile than JPM relative to the S&P 500. On balance sheet safety, SIGA Technologies, Inc. (SIGA) carries a lower debt/equity ratio of 0% versus 4% for Dyadic International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -64. 7% for Dyadic International, Inc. (DYAI). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -185. 0% for Oragenics, Inc.. Over a 3-year CAGR, OCGN leads at 21. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -1537. 4% for Ocugen, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -1425. 7% for OCGN. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, SIGA Technologies, Inc.

(SIGA) trades at 2. 5x forward P/E versus 14. 6x for JPMorgan Chase & Co. — 12. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OCGN: 303. 2% to $5. 00.

In this comparison, SIGA (13.

9% yield), JPM (1. 8% yield) pay a dividend. OGEN, NVAX, DYAI, OCGN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, SIGA Technologies, Inc.

(SIGA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92), 13. 9% yield, +642. 9% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SIGA: +642. 9%, NVAX: -93. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OGEN (Healthcare) and SIGA (Healthcare) and NVAX (Healthcare) and DYAI (Healthcare) and OCGN (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OGEN is a small-cap quality compounder stock; SIGA is a small-cap deep-value stock; NVAX is a small-cap high-growth stock; DYAI is a small-cap quality compounder stock; OCGN is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. SIGA, JPM pay a dividend while OGEN, NVAX, DYAI, OCGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.